Warp Sciences exits stealth with $215M to apply robotics to drug discovery

Warp Sciences has emerged from stealth with $215 million in funding led by Lightspeed. The South San Francisco startup is building a U.S.-based chemistry CRO that combines chemists, robotics and AI to synthesize and test molecules for biotech and pharma partners, starting with lead optimization analog synthesis.

Robotics Business Review

Open source

Warp Sciences exits stealth with $215M to apply robotics to drug discovery

Lightspeed led the round, with Menlo Ventures, Lux, IVP and others participating
CEO Kevin Weil previously served as chief product officer and VP of science at OpenAI
The company has no proprietary drug pipeline and focuses on generating data for AI
Initial service is lead optimization analog synthesis for drug discovery teams

#WarpSciences#OpenAI#Lightspeed

Warp Sciences exits stealth with $215M to apply robotics to drug discovery

Anthropic expands Claude's life sciences ecosystem for drug discovery

Anthropic's new science lab announced its first major discovery

Warp adds programmable AI agents to its HR platform

Seattle’s Nuance Labs raises $50M to give AI models human expression and nuance